healthcare investor
What will be the biggest biotech development over the next decade? What cutting-edge treatment will change our perspective on common diseases? Curiosity is an important part of our business DNA – together with our strong belief in long-term value creation.
P53 was founded in November 2018. We are part of the family-owned Stavanger based investment company TD Veen. All investments are made in line with TD Veen’s overall strategy and objective, where sustainable development and a scalable business model are particularly emphasized. However, P53 is solely dedicated to the healthcare sector.
In our core investments, P53 shall be an active owner, preferably with one or more co-investors who are considered to share our approach and mindset. In addition to long-term capital, we aim to contribute with our knowledge, experience, and network. Our active positions are exercised through (active) board participation and in close collaboration with the company’s management and other shareholders.
We work closely with entrepreneurs and management to build competitive healthcare companies that we can be proud of. In addition to long-term capital, P53 will make valuable contributions in the form of knowledge, experience, and networking through active ownership.